Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kewaunee Scientific (KEQU) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Kewaunee Scientific (KEQU) over the last 16 years, with Q4 2025 value amounting to -$4.3 million.

  • Kewaunee Scientific's Cash from Operations fell 15055.71% to -$4.3 million in Q4 2025 from the same period last year, while for Oct 2025 it was $8.7 million, marking a year-over-year decrease of 5260.57%. This contributed to the annual value of $14.8 million for FY2025, which is 2443.77% down from last year.
  • As of Q4 2025, Kewaunee Scientific's Cash from Operations stood at -$4.3 million, which was down 15055.71% from $5.8 million recorded in Q3 2025.
  • Kewaunee Scientific's Cash from Operations' 5-year high stood at $9.5 million during Q1 2024, with a 5-year trough of -$6.8 million in Q2 2022.
  • Over the past 5 years, Kewaunee Scientific's median Cash from Operations value was $252000.0 (recorded in 2023), while the average stood at $1.3 million.
  • Examining YoY changes over the last 5 years, Kewaunee Scientific's Cash from Operations showed a top increase of 305043.48% in 2021 and a maximum decrease of 38777.78% in 2021.
  • Kewaunee Scientific's Cash from Operations (Quarter) stood at -$4.3 million in 2021, then rose by 0.56% to -$4.3 million in 2022, then soared by 117.49% to $747000.0 in 2023, then surged by 1029.32% to $8.4 million in 2024, then crashed by 150.56% to -$4.3 million in 2025.
  • Its Cash from Operations stands at -$4.3 million for Q4 2025, versus $5.8 million for Q3 2025 and $9.4 million for Q2 2025.